SG10201602424RA - Antigen Presenting Cancer Vaccine With Gamma Interferon - Google Patents

Antigen Presenting Cancer Vaccine With Gamma Interferon

Info

Publication number
SG10201602424RA
SG10201602424RA SG10201602424RA SG10201602424RA SG10201602424RA SG 10201602424R A SG10201602424R A SG 10201602424RA SG 10201602424R A SG10201602424R A SG 10201602424RA SG 10201602424R A SG10201602424R A SG 10201602424RA SG 10201602424R A SG10201602424R A SG 10201602424RA
Authority
SG
Singapore
Prior art keywords
antigen presenting
cancer vaccine
gamma interferon
presenting cancer
interferon
Prior art date
Application number
SG10201602424RA
Inventor
Andrew Cornforth
Robert Dillman
Original Assignee
California Stem Cell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Stem Cell Inc filed Critical California Stem Cell Inc
Publication of SG10201602424RA publication Critical patent/SG10201602424RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201602424RA 2011-10-20 2012-10-22 Antigen Presenting Cancer Vaccine With Gamma Interferon SG10201602424RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549681P 2011-10-20 2011-10-20
US201261594304P 2012-02-02 2012-02-02

Publications (1)

Publication Number Publication Date
SG10201602424RA true SG10201602424RA (en) 2016-05-30

Family

ID=48141460

Family Applications (4)

Application Number Title Priority Date Filing Date
SG11201401632WA SG11201401632WA (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine
SG10201508535RA SG10201508535RA (en) 2011-10-20 2012-10-22 Antigen Presenting Cancer Vaccine
SG10201602424RA SG10201602424RA (en) 2011-10-20 2012-10-22 Antigen Presenting Cancer Vaccine With Gamma Interferon
SG11201401631VA SG11201401631VA (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11201401632WA SG11201401632WA (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine
SG10201508535RA SG10201508535RA (en) 2011-10-20 2012-10-22 Antigen Presenting Cancer Vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201401631VA SG11201401631VA (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon

Country Status (11)

Country Link
US (2) US20140308316A1 (en)
EP (2) EP2768534A4 (en)
JP (2) JP2014533938A (en)
KR (2) KR20150004791A (en)
CN (5) CN105861437A (en)
AU (2) AU2012325758A1 (en)
CA (2) CA2852960A1 (en)
HK (2) HK1201176A1 (en)
IL (2) IL232172A0 (en)
SG (4) SG11201401632WA (en)
WO (2) WO2013059784A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865830B1 (en) 2004-01-30 2006-05-19 Neopost Ind SECURED EXTERNAL PRINT MODE MAIL POSTAGE SYSTEM
SG11201401632WA (en) * 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine
CN103599528B (en) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 The preparation method of human dendritic cell vaccine
JP6967963B2 (en) * 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. Production of multi-dose injection-prepared dendritic cell vaccine and combination therapy to block HER2 and HER3
JP2019514396A (en) * 2016-05-05 2019-06-06 ナントミクス，エルエルシー Checkpoint failure and methods related thereto
CA3053939A1 (en) * 2017-02-17 2018-08-23 Aivita Biomedical, Inc. Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells
WO2024107624A1 (en) * 2022-11-14 2024-05-23 Shattuck Labs, Inc. Methods of overcoming resistance to checkpoint inhibitor therapies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669379B2 (en) * 1992-09-07 1996-06-06 Kyowa Hakko Kirin Co., Ltd. Humanized antibodies
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2321093A1 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
ES2340358T3 (en) 1999-10-15 2010-06-02 Baylor Research Institute USE OF ALLOGENIC CELL LINES TO LOAD CELLS THAT PRESENT ANTIGENS TO CHOOSE IMMUNE ANSWERS.
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
RU2313365C2 (en) * 2001-11-29 2007-12-27 Дандрит Байотек А/С Pharmaceutical composition for inducing of immune response in human
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
CN1443778A (en) * 2002-03-13 2003-09-24 上海中信国健药业有限公司 Monoclonal antibody of melanic related antigen, and its application and medicine composition
CN101052709B (en) 2004-10-25 2012-06-27 贝勒研究院 Dendritic cells loaded with heat shocked melanoma cell bodies
JP5281399B2 (en) 2005-07-29 2013-09-04 プロビデンス ヘルス システム Incomplete ribosome products in vesicles (DRIBBLE) and methods of use for stimulating immune responses
CA2628477A1 (en) * 2005-11-07 2007-05-10 Bc Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
CA2691346A1 (en) * 2006-06-30 2008-01-10 Baylor Research Institute Dendritic cells generated using gm-csf and interferon alpha and loaded with heat-treated and killed cancer cells
AR060424A1 (en) 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec CELLULAR LINES, COMPOSITIONS FOR THE TREATMENT OF MELANOMS THAT UNDERSTAND PROCEDURES TO PREPARE COMPOSITIONS AND TREATMENT METHODS
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same
SG11201401632WA (en) 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine

Also Published As

Publication number Publication date
EP2768534A1 (en) 2014-08-27
EP2768519A4 (en) 2015-07-01
SG11201401631VA (en) 2014-05-29
SG10201508535RA (en) 2015-11-27
CA2852967A1 (en) 2013-04-25
HK1201176A1 (en) 2015-08-28
AU2012325758A1 (en) 2014-04-24
SG11201401632WA (en) 2014-05-29
KR20150016200A (en) 2015-02-11
US20140314814A1 (en) 2014-10-23
EP2768534A4 (en) 2015-04-01
WO2013059778A2 (en) 2013-04-25
HK1201175A1 (en) 2015-08-28
JP2014530627A (en) 2014-11-20
US9555058B2 (en) 2017-01-31
CN103917246A (en) 2014-07-09
JP2014533938A (en) 2014-12-18
NZ623917A (en) 2016-09-30
AU2012325764A1 (en) 2014-04-24
CN105288602A (en) 2016-02-03
CN105999249A (en) 2016-10-12
CN105861437A (en) 2016-08-17
EP2768519A2 (en) 2014-08-27
CA2852960A1 (en) 2013-04-25
IL232173A0 (en) 2014-06-30
NZ623915A (en) 2016-02-26
US20140308316A1 (en) 2014-10-16
CN103957925A (en) 2014-07-30
WO2013059778A3 (en) 2013-07-04
IL232172A0 (en) 2014-06-30
WO2013059784A1 (en) 2013-04-25
KR20150004791A (en) 2015-01-13

Similar Documents

Publication Publication Date Title
HK1207962A1 (en) Mycobacterial antigen vaccine
HK1197182A1 (en) Cancer immunotherapy
EP2714073A4 (en) In situ antigen-generating cancer vaccine
PT3473267T (en) Individualized vaccines for cancer
HK1201175A1 (en) Antigen presenting cancer vaccine with gamma interferon
IL231043A0 (en) Vaccine
GB201120860D0 (en) Cancer immunotherapy
GB201119999D0 (en) Vaccine
GB201003293D0 (en) Cancer vaccine
ZA201402071B (en) Vaccine therapy
EP2771453A4 (en) Diatom-based vaccines
HK1202070A1 (en) Vaccine for tumor immunotherapy
EP2763699A4 (en) Vaccine
HK1209455A1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
GB201120000D0 (en) Vaccine
GB201107549D0 (en) Cancer vaccine
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine
GB201108982D0 (en) Vaccines
GB201108984D0 (en) Vaccines
GB201108986D0 (en) Vaccines